PARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD by 源�誘몃━ et al.
232 Ann Dermatol
Received February 8, 2010, Revised May 19, 2010, Accepted for 
publication June 14, 2010
Corresponding author: Min-Geol Lee, M.D., Department of Derma-
tology and Cutaneous Biology Research Institute, Yonsei University 
College of Medicine, 134 Sinchon-dong, Seodaemun-gu, Seoul 
120-752, Korea. Tel: 82-2-2228-2080, Fax: 82-2-393-9157, E-mail: 
mglee@yuhs.ac
Ann Dermatol Vol. 23, No. 2, 2011 DOI: 10.5021/ad.2011.23.2.232
CASE REPORT
LEOPARD Syndrome with PTPN11 Gene Mutation 
Showing Six Cardinal Symptoms of LEOPARD
Jihyun Kim, M.D., Mi Ri Kim, M.D., Hee Jung Kim, M.D., Kyung-A Lee, M.D.1, Min-Geol Lee, M.D.
Department of Dermatology and Cutaneous Biology Research Institute, 1Department of Laboratory Medicine, Yonsei University College of 
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LEOPARD multiple congenital anomaly syndrome inherited 
in an autosomal dominant manner. LEOPARD is an acronym 
for Lentigines, Eletrocardiographic conduction defects, 
Ocular hypertelorism, Pulmonary valve stenosis, Abnor-
malities of the genitalia, Retardation of growth, and 
Deafness. Clinical diagnosis is primarily based on multiple 
lentigines, typical facial features, and the presence of 
hypertrophic cardiomyopathy and/or café-au-lait macules. 
We report a typical case of LEOPARD syndrome with 
PTPN11 gene mutation associated with lentigines, electro-
cardiograph abnormality, ocular hypertelorism, pulmonary 
valve stenosis, growth retardation, and sensorineural hearing 
loss. (Ann Dermatol 23(2) 232∼235, 2011)
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INTRODUCTION
LEOPARD syndrome (LS) is a multiple congenital anomaly 
syndrome inherited in an autosomal dominant manner. It 
has high penetrance and markedly variable phenotypic 
expression. Diagnostic clues to LS include multiple lenti-
gines, café-au-lait macules, hypertrophic cardiomyopathy, 
and deafness. To date, about 200 LS patients have been 
reported globally. It has recently been reported that LS is 
related to PTPN11 gene mutation1, which is located on 
chromosome 12q24.1. Herein, we report a case of typical 
LS associated with PTPN11 gene mutation.
CASE REPORT
A 16 year-old male visited our clinic with multiple dark 
macules of varying size over his whole body from the age 
of 2 years associated with pigmented macules on the face, 
trunk, and upper extremities (Fig. 1). He had been 
diagnosed as hypertrophic cardiomyopathy (HCMP) at the 
age of 1 and for which he has been managed with a beta 
blocker. In addition, he developed severe bilateral neu-
ronal deafness and underwent a cochlear implant in his 
right ear at the age of 5. His development suffers delay: he 
sat at 1 year, walked at 2 years, and experienced speech 
delay. His height and weight were below the 25th per-
centile. However, no other family members are similarly 
affected.
Physical examination revealed ocular hypertelorism (inter-
pupillary distance 5.6 cm, >97th percentile), mandibular 
prognathism, and posteriorly rotated ears. His genitalia 
was normal on physical examination. Twelve-lead electro-
cardiograph (EKG) (Fig. 2) showed right-axis deviation, 
ST-segment abnormalities, and T-wave inversion. Echocar-
diogram (Fig. 3) showed hypertrophic obstructive car-
diomyopathy with thickened interventricular septum and 
systolic anterior motion of the mitral valve leaflets. 
However, there were no abnormalities on chromosomal 
study. Skin biopsies were performed on the face and 
trunk. Histopathologically, the lesion from the trunk 
showed a slight elongation of the rete ridges and increase 
in melanocyte concentration in the basal layer (Fig. 4). 
The pathologic diagnosis was consistent with lentigo 
simplex. Based upon the clinical, pathologic, and echo-
cardiographic findings, a diagnosis of LS was made. After 
obtaining the patient’s consent, mutation analysis of 
PTPN11 was performed. Genomic DNA for germ-line 
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Fig. 1. (A) Numerous brownish 
macules on the face with ocular 
hypertelorism. (B) Low set, post-
eriorly rotated ears and mandibular 
prognathism.
Fig. 2. Twelve-lead EKG shows right-axis deviation, ST-segment
abnormalities and T-wave inversion.
Fig. 3. Echocardiographic analysis showed hypertrophic obstruc-
tive cardiomyopathy with thickened interventricular septum and 
systolic anterior motion of the mitral valve leaflets.
Fig. 4. Histopathologic findings of pigmented macules revealed
slight elongation of the rete ridges with increased melanocytes 
in the basal layer (H&E stain, ×100).
mutation analyses was prepared from peripheral blood 
leukocytes. We performed polymerase chain reaction 
amplification of all 15 exons and introns of PTPN11, and 
sequenced all of exon and intron junctions bilaterally. We 
found missense mutation (836A3G; Tyr279Cys) in exon 7 
(Fig. 5).
We treated the lentigines on face with a triple combi-
nation cream of 0.05% tretinoin, 4.0% hydroquinone, and 
0.01% fluocinolone acetonide (Tri-LumaⓇ, Hill Derma-
ceutical, Inc., Stanford, CA, USA) and the affected lesions 
showed slight improvement after 2 months of therapy.
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Fig. 5. Mutation analysis of PTPN11 gene revealed a missense
mutation 836A→G in exon 7.
DISCUSSION
The LS is coined by Gorlin et al.2 in 1969 based on an 
acronym of multiple lentigines, EKG conduction abnor-
malities, ocular hypertelorism, pulmonary stenosis, abnor-
mal genitalia, growth retardation, and sensorineural 
deafness. This condition is also known as multiple len-
tigines syndrome, cardio-cutaneous syndrome, Moynahan 
syndrome, lentiginosis profusa, and progressive car-
diomyopathic lentiginosis. About 200 patients have been 
reported in the English literature, but only seven cases of 
LS have been reported in the Korean dermatologic 
literature3-9.
The most plausible explanation for the pathogenesis of LS 
is neural crest cell abnormality associated with PTPN11 
gene mutation, which codes for non-receptor protein 
tyrosine phosphatase, SHP21,10, which plays important 
roles in cell proliferation, differentiation, migration and 
adhesion. To the best of our knowledge, only 11 different 
missense PTPN11 mutations in exon 7, 12 and 13 have 
been reported. Recently, missense mutations in the RAF1 
gene have been found in two out of six PTPN11-negative 
LS patients11. However, all of 7 reported LS cases in the 
Korean dermatologic literature did not include mutation 
analysis of the PTPN11 gene. In our patient, mutation 
analysis of the PTPN11 gene revealed a missense 
mutation (836A→G; Tyr279Cys) in exon 7, which is one 
of two frequent mutations that constitute more than 60% 
of cases. We did not, however, investigate for RAF1 gene 
mutation.
The presence of lentigines remains an aesthetic problem, 
since malignant transformation of the lentigines has not 
been reported. Kontoes et al.12 reported successful use of 
intense pulsed light for the treatment of lentigines in a 
patient with LS. Lee et al.9 reported that alexandrite laser 
treatment was effective for the treatment of lentigines in a 
11-year-old patient with LS. Our patient was treated by 
triple combination cream containing 0.05% tretinoin, 
4.0% hydroquinone, and 0.01% fluocinolone acetonide 
(Tri-LumaⓇ) for 6 weeks and slight improvement was 
noted.
In general, the long-term prognosis of LS patients varies 
with the type of cardiac anomalies. Among patients with 
PTPN11 mutation, an association between exon 7 and 
exon 12 mutations with HCMP has been established13. 
Our patient experienced cyanosis and dyspnea after 
delivery secondary to HCMP with pulmonary valve 
stenosis for which he is undergoes periodic cardiology 
assessment. In addition, Seishima et al.14 suggested that 
PTPN11 mutation have specific tumorigenic effect re-
cently. Due to the rarity of malignant cases associated 
with LS, the association is inconclusive. However, acute 
lymphoblastic leukemia15, acute myeloid leukemia16, and 
multiple granular cell tumor17 associated with LS with 
mutation in PTPN11 gene have been reported. Although 
predisposition of malignancy in LS remains debatable, LS 
patients with PTPN11 mutations should be closely 
monitored for malignancy, particularly during their 
childhood. Identification of PTPN11 gene mutation in LS 
would be a good marker to estimate prognosis. Our 
patient receives regular dermatological review to monitor 
for the development of malignancy.
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